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Therapeutic Recommendations
There is no new evidence that conflicts with the pre-
vious recommendations regarding injection therapies pub-
lished in the original version of the “Guidelines for the per-
formance of fusion procedures for degenerative disease of 
the lumbar spine.”27
Lumbar Epidural Steroid Injections
Grade C
Lumbar epidural steroid injections (ESIs) are an op-
tion for the short-term relief of chronic low-back pain 
without radiculopathy in patients with degenerative dis-
ease of the lumbar spine (Level III evidence).
Caudal ESIs are an option for decreasing low-back 
pain of greater than 6 weeks’ duration, without radiculop-
athy, in patients with degenerative disease of the lumbar 
spine (Level III evidence).
Lumbar Facet Injections
Grade B
Intraarticular injections of lumbar facet joints are 
not suggested for the treatment of facet-mediated chronic 
low-back pain without radiculopathy in cases of degen-
erative disease of the lumbar spine (single Level II study 
and single Level III study).
Lumbar medial nerve blocks are suggested for the 
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The medical literature continues to fail to support the use of lumbar epidural injections for long-term relief of 
chronic back pain without radiculopathy. There is limited support for the use of lumbar epidural injections for short-
term relief in selected patients with chronic back pain. Lumbar intraarticular facet injections are not recommended 
for the treatment of chronic lower-back pain. The literature does suggest the use of lumbar medial nerve blocks for 
short-term relief of facet-mediated chronic lower-back pain without radiculopathy. Lumbar medial nerve ablation 
is suggested for 3–6 months of relief for chronic lower-back pain without radiculopathy. Diagnostic medial nerve 
blocks by the double-injection technique with an 80% improvement threshold are an option to predict a favorable 
response to medial nerve ablation for facet-mediated chronic lower-back pain without radiculopathy, but there is no 
evidence to support the use of diagnostic medial nerve blocks to predict the outcomes in these same patients with 
lumbar fusion. There is insufficient evidence to support or refute the use of trigger point injections for chronic lower-
back pain without radiculopathy.
(http://thejns.org/doi/abs/10.3171/2014.4.SPINE14281)
Key WorDs      •      fusion      •      lumbar spine      •      epidural steroid injection      •       
facet block      •      trigger point injection      •      low-back pain      •      practice guidelines
Abbreviations used in this paper: ESI = epidural steroid injection; 
NRS = Numerical Rating Scale; ODI = Oswestry Disability Index; 
RCT = randomized control trial; TPI = trigger point injection; VAS 
= visual analog scale.
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short-term relief of facet-mediated chronic low-back pain 
without radiculopathy in patients with degenerative disease 
of the lumbar spine (single Level II study and single Level 
III study).
Lumbar medial nerve ablation is suggested for the 
short-term (3- to 6-month) relief of facet-mediated pain in 
patients who have chronic lower-back pain without radic-
ulopathy from degenerative disease of the lumbar spine (4 
Level II studies).
Lumbar Trigger Point Injections
Grade B
Trigger point injections (TPIs) performed as dry 
needling, with anesthetics alone or with steroids, are not 
recommended in patients with chronic low-back pain 
without radiculopathy from degenerative disease of the 
lumbar spine because a long-lasting benefit has not been 
demonstrated (Level II evidence).
Diagnostic Recommendations
Grade B
To establish the diagnosis of lumbar facet-mediated 
pain, the double-injection technique with an improvement 
threshold of 80% or greater is suggested (single Level I 
study).
Grade C
Diagnostic facet blocks by the double-injection tech-
nique with an improvement threshold of 80% are an op-
tion for predicting a favorable response to facet medial 
nerve ablation by thermocoagulation for facet-mediated 
chronic low-back pain without radiculopathy in patients 
with degenerative disease of the lumbar spine (single 
Level II study).
Grade I: Inconclusive
There is no evidence to support the use of diagnos-
tic facet blocks as a predictor of lumbar fusion outcome 
in patients with chronic low-back pain from degenerative 
lumbar disease (conflicting Level IV evidence).
Rationale
Since the original publication of the Lumbar Fu-
sion Guidelines, injection techniques using an anesthetic 
agent, typically in combination with a steroid, continue to 
be widely used in the treatment of patients with chronic 
low-back pain.27 An updated analysis of the literature re-
garding these treatments was performed from July 2003, 
the termination point of the previous guidelines, through 
the end of 2011. As was the case in the original guide-
lines, an attempt was made to answer 3 questions:
1) Are lumbar ESIs effective for improving the out-
comes of patients with chronic low-back pain resulting 
from degenerative disease of the lumbar spine?
2) Are lumbar facet injections effective for improv-
ing the outcomes of patients with chronic low-back pain 
resulting from degenerative disease of the lumbar spine?
3) Are lumbar TPIs effective for improving the out-
comes of patients with chronic low-back pain resulting 
from degenerative disease of the lumbar spine?
Search Criteria
A computerized search of articles published from 
July 2003 through the year 2011 in the National Library 
of Medicine’s MEDLINE database was conducted using 
the online search engine “PubMed.” The search chain 
included the following terms: (“low back pain”[MeSH 
Terms] OR (“low”[All Fields] AND “back”[All Fields] 
AND “pain”[All Fields]) OR “low back pain”[All Fields]) 
AND (“Injections, Spinal”[MeSH] OR “Injections, Intra-
Articular”[MeSH] OR “Anesthesia, Epidural”[MeSH] 
OR “Nerve Block”[MeSH] OR trigger point injection 
[title] OR trigger point injections[title] OR (facet joint 
injection[title] OR facet joint injections[title] OR (epidur-
al steroid injection[title] OR epidural steroid injections 
[title]) OR epidural steroid block[title] OR (caudal in-
jection[title] OR caudal injections[title]) OR (caudal 
block[title] OR caudal blockade[title] OR caudal blocks 
[title]) OR (selective nerve root injection[title] OR selec-
tive nerve root injections[title]) OR (selective nerve root 
block[title] OR selective nerve root blocks[title]) OR 
(transforaminal injection[title] OR transforaminal in-
jections[title] OR (transforaminal block[title] OR trans-
foraminal blocks[title])) OR (block[title] OR block/
activation[title] OR block/cytological[title] OR block/intra 
osseous[title] OR block/mylohyoid[title] OR block/neu 
rolysis[title] OR block/sick[title] OR block/western[title] 
OR block’[title] OR block’s[title] OR block98[title] OR 
blockable[title] OR blockad[title] OR blockada[title] 
OR blockade[title] OR blockade/myosin[title] OR block 
ade/thiazide[title] OR blockade’[title] OR blockaded 
[title] OR blockaden[title] OR blockader[title] OR block 
aders[title] OR blockaders/admin[title] OR blockades 
[title] OR blockading[title] OR blockador[title] OR block 
age[title] OR blockages[title] OR blockain[title] OR 
blockaine[title] OR blockal[title] OR blockase[title] OR 
blockboard[title] OR blockbuilding[title] OR block 
buster[title] OR blockbuster’[title] OR blockbusters[title] 
OR blockcourse[title] OR blockcycler[title] OR block 
dissection[title] OR blocke[title] OR blocked[title] OR 
blocked’[title] OR blocker[title] OR blocker/5[title] OR 
blocker/beta[title] OR blocker/calcium[title] OR blocker/ 
carbonic[title] OR blocker/diuretic[title] OR blocker/drug 
[title] OR blocker/hydrochlorothiazide[title] OR blocker/ 
statin[title] OR blocker/thiazide[title] OR blocker/vaso 
dilator[title] OR blocker’s[title] OR blockerette[title] OR 
blockers[title] OR blockers/ace[title] OR blockers’[title] 
OR blockes[title] OR blockexcision[title] OR blockface 
[title] OR blockheads[title] OR blockholer[title] OR 
blocki[title] OR blockinducing[title] OR blockiness[title] 
OR blocking[title] OR blocking/deblocking[title] OR 
blocking/diuretic[title] OR blocking/percolation[title] OR 
blocking/unblocking[title] OR blocking’[title] OR block 
ings[title] OR blocklength[title] OR blockley[title] OR 
blockmakers[title] OR blockmaking[title] OR blockmilk 
[title] OR blockout[title] OR blockpnea[title] OR block 
polymer[title] OR blocks[title] OR blocks’[title] OR block 
sequences[title] OR blockset[title] OR blocksom[title] OR 
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blockwise[title] OR blockwriting[title] OR blocky[title] 
OR blockypnea[title] OR blockzone[title]) OR (facet 
joint block[All Fields] OR facet joint blocks[All Fields]) 
OR (median nerve block[title] OR median nerve block 
ade[title]) OR median nerve injection[title] OR (trigger 
point injection[title] OR trigger point injections[title]) 
OR (trigger[All Fields] AND (point block[title] OR point 
blocks[title])))) AND ((“Lumbosacral Region”[MeSH] 
OR “Lumbar Vertebrae”[MeSH]) OR lumbar[title]) 
AND ((“2003”[PDAT]: “3000”[PDAT]) AND “humans” 
[MeSH Terms] AND English[lang]).
The search was limited to English-language publica-
tions and human subjects. Nonsystematic reviews were 
discarded, but the bibliographies from these papers were 
searched for any additional relevant references. The search 
yielded 249 new references for this paper. Papers selected 
were confined to studies of chronic low-back pain (> 3–6 
months) due to lumbar degenerative disease without defor-
mity and without radiculopathy. The results of the search 
were divided into 3 categories depending on the type of 
injection investigated: ESIs, facet injections, and TPIs. All 
papers providing Level II or better evidence were included. 
In the absence of Level 1 or Level II data, Level III papers 
were included in the analysis. Papers with Level IV evi-
dence were referenced in the discussion but not included in 
the evidentiary tables.
Scientific Foundation
Use of Lumbar ESIs (Interlaminar Injections, Caudal  
Injections, Transforaminal Injections) in the Treatment of 
Chronic Low-Back Pain Due to Degenerative Disease of 
the Lumbar Spine
Epidural injections continue to be used extensively 
in the treatment of spinal pain.11,34 The evaluation of ESIs 
for chronic lower-back pain without radiculopathy re-
mains minimal. In the previous review of this topic,27 4 
randomized control trials (RCTs) were found to evaluate 
the effectiveness of epidural injections in the treatment 
of chronic lower-back pain.4,9,28,30 All 4 of these studies 
were reported as RCTs but were greatly underpowered 
and represented equivalence trials without true control 
groups. By the criteria of the current report, these studies 
are classified as Level III data and give little support for 
the use of lumbar ESIs in chronic back pain for anything 
more than short-term relief (< 2 weeks). They are refer-
enced in the bibliography but not in the evidence table 
(see Table 1). Since the completion of the previous review 
of this topic, a prospective cohort study published in 2004 
by Buttermann evaluated 232 patients, age 18–65 years, 
with low-back pain of greater than 1 year in duration, in 
whom conservative maneuvers failed.5 The patients were 
diagnosed with degenerative disc disease without stenosis 
or listhesis. They received 1–3 interlaminar or transfo-
raminal steroid injections guided by fluoroscopy and were 
followed up for up to 2 years. Modic endplate changes on 
MRI, indicative of vertebral inflammation, were observed 
in 93 of the study participants. Buttermann predicted that 
these participants would appreciate more frequent relief 
of low-back pain after ESIs than would the group with-
out inflammatory changes. Validated outcome measures 
were used, including the visual analog scale (VAS), Os-
westry Disability Index (ODI), and pain drawings. Medi-
cation usage and the degree of patient satisfaction were 
also recorded. A subgroup of patients was randomized to 
receive a discogram with or without steroids. For patients 
with inflammatory endplate changes, 55% were satisfied 
with the degree of pain relief up to 3 months after the 
injection, although a clinically relevant improvement was 
not observed in the VAS or ODI scores. A similar finding 
was observed in the noninflammatory cohort with 47% 
satisfied. Improvement in both groups declined over time. 
While the baseline differences in ODI scores between the 
two groups was not different prior to treatment, compari-
son of these scores for the two groups at 3- and 6-month 
follow-up showed a statistically greater improvement for 
the group with inflammatory changes (p < 0.001), though 
neither group demonstrated a statistically significant im-
provement over baseline scores. This study has been cited 
as providing support for the short-term benefit of ESIs 
in decreasing chronic low-back pain, although there was 
no objective improvement in either group observed with 
the validated outcome measures. Furthermore, the con-
clusions of the study are severely compromised by the 
high dropout rate at final follow-up: 51% of the original 
patients in the inflammatory group and 60% of those in 
the noninflammatory cohort were lost to follow-up. In an 
equivalence trial, Manchikanti et al. published a random-
ized controlled and double-blinded study of 70 patients 
with lower-back pain and no radiculopathy or evidence of 
disc herniation on MRI.19 Thirty-five of the patients were 
randomized to Group I in which the patients received in-
terlaminar injections of anesthetic only and 35 were ran-
domized to Group II in which the patients received inter-
laminar injections of an anesthetic and a steroid. Validated 
outcomes measures, including the ODI for functional as-
sessment and the Numerical Rating Scale (NRS), were 
recorded at baseline and at 3, 6, and 12 months. Greater 
than a 50% improvement in pain or function from base-
line was required for significance. Significant pain relief 
was recorded in 74% of Group I and 63% of Group II, 
while significant functional improvement was achieved in 
71% of Group I and 60% of Group II. The overall aver-
age number of injections for the two groups over the year 
of follow-up was 4. This study, while suggestive, suffers 
from being an equivalence study without appropriate pla-
cebo control, from being underpowered, and from being 
a preliminary report.
Three systematic reviews were identified during the 
current search (Table 1). Abdi et al. performed a review 
of the literature from published 1966 to 2006 on cervical, 
thoracic and lumbar ESIs.1 For the lumbar spine, 13 ran-
domized control trials (RCTs) studies for transforaminal 
injections, and 8 RCTs and 5 prospective trials for caudal 
injections. The majority of these studies investigated the 
utility of these treatments for radiculopathy. With respect 
to chronic low-back pain, the Buttermann study, reviewed 
above, was felt to provide indeterminate evidence that 
ESIs were effective in managing chronic low-back pain 
when the transforaminal and interlaminar techniques 
were used.5 In addition, the authors concluded there was 
W. C. Watters III et al.
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moderate evidence in support of short- and long-term 
improvement in managing chronic low-back pain via the 
caudal approach. In 2009, Staal et al. published an update 
of a previous Cochrane Review, evaluating the literature 
from 1999 to March 2007 in patients 18–70 years of age.32 
Only RCTs involving facet, epidural, and local injections 
were considered. The authors noted that since their initial 
publication in 2001,25 there was no apparent improvement 
in the quality of the evidence. With respect to ESIs for 
chronic low-back pain, the authors concluded that there 
was moderate evidence that ESIs are no more effective 
than a placebo for pain relief, that there is limited evi-
dence ESIs and placebo are equally effective for general 
improvement in the work-disability population, and that 
there is limited evidence ESIs are more effective than 
other drug treatments. Parr et al. published a systematic 
review of studies published between 1966 and 2008 on 
lumbar interlaminar injections for the management of 
chronic low-back pain with and without radiculopathy.26 
They noted that the majority of these studies were done 
without fluoroscopic guidance. None of the RCTs iden-
tified investigated chronic low-back pain in the absence 
of a radiculopathy, and of the 30 observational studies, 
only the Buttermann article evaluated patients with iso-
lated chronic low-back pain.5 The authors concluded that 
the Buttermann article suggested some short-term but no 
long-term effect for ESIs on chronic lower-back pain.
Use of Lumbar Facet Injections for Chronic Low-Back 
Pain Due to Degenerative Disease of the Lumbar Spine
Lumbar facet (zygapophysial) joint injections have 
been used for both the diagnosis and treatment of facet-
mediated low-back pain. Facet-mediated pain patterns 
have been explored by mapping the response to facet 
provocation and anesthesia injections in volunteers. These 
studies have yet to demonstrate a reliable pattern of pain 
produced by an injection within a particular lumbar facet 
joint.7 When the data are combined from multiple studies, 
patterns emerge that suggest there is considerable over-
lap among all lumbar facet joints. Pain from the lower 
facet joints can be referred to the groin and deep posterior 
thigh, while the upper joints can lead to pain in the flank, 
hip, and upper lateral thigh. Pain referred below the knee 
is highly questionable. No physical or radiographic find-
ings consistently correlate with the observations follow-
ing facet blocks,7 and the diagnosis of facet-mediated pain 
continues to rely on appropriately performed diagnostic 
facet blocks. The results of so-called double-block stud-
ies suggest that facet-mediated low-back pain is a cause 
of chronic pain in 9%–42% of patients with degenerative 
lumbar disease.2,7,10,18,29
Studies investigating the role of diagnostic facet joint 
blocks have been conducted in an attempt to improve the 
accuracy of this technique. Since the original guideline 
publication, a more uniform definition of a valid response 
has been adopted. It has been suggested that the double-
block technique is the most reliable means of identify-
ing facet-mediated pain, although this procedure is rarely 
performed during routine clinical practice. In the double-
block technique, facet blocks are performed on two dif-
ferent dates with anesthetics that vary with respect to du-
ration of the analgesic effect. A positive response requires 
that the patient’s low-back pain significantly improve fol-
lowing both blocks for a period of time consistent with 
the anesthetic’s duration of action.2 To further refine the 
specificity of diagnostic facet injections, it has been sug-
gested that the traditional threshold of greater than 50% 
pain relief be increased to greater than 80%. In a sys-
tematic review of 7 studies, Datta et al. presented Level 
I and II diagnostic evidence that the use of double con-
trolled blocks and an 80% pain relief threshold produced 
the highest specificity in diagnosing facet-mediated back 
pain (Table 2).10 They recommended that all future sys-
tematic reviews and investigations use these parameters 
as valid criteria to diagnose facet-mediated pain and 
evaluate the response to treatment. In an observational 
study, Manchikanti et al. demonstrated the improved sus-
tainability of the diagnosis of lumbar facet-mediated pain 
at 2-year follow-up when comparing a group in which 
the 80% threshold was used for diagnosis and a group 
in which a 50% threshold for pain relief was used for di-
agnosis.20 The diagnosis of facet-mediated pain was sus-
tained in 89.5% of the patients diagnosed with the dou-
ble-injection technique and an 80% threshold at 2 years 
versus only 51% of patients diagnosed with a double in-
jection technique and a 50% threshold. The authors point 
out that utilizing the double-injection technique and an 
80% threshold will diminish inappropriate and unneces-
sary treatment.20
Therapeutic facet blocks can be delivered in one of 
two manners: as an intraarticular injection into a facet 
joint or as a neural block of the medial nerve that in-
nervates the facet capsule. In the previous review of 
this topic, 3 Level II studies addressed the efficacy of 
intraarticular injections in the facet joint.6,17,23 Lilius et 
al. randomly assigned patients to one of three groups.17 
Group I received an intrafacet injection of steroid and an-
esthetic; Group II, pericapsular injections of steroid and 
anesthetic; and Group III, pericapsular injections of sa-
line. The authors concluded that facet injections were a 
nonspecific form of treatment of lower-back pain that had 
good results depending more on psychosocial aspects of 
back pain. Carette et al. randomized 91 patients to facet 
injections of either methylprednisolone or saline.6 No 
differences were seen between the groups at 1, 3, and 6 
months postinjection. The authors concluded that injec-
tion of methylprednisolone into facet joints was of little 
treatment value. Marks et al. randomized 86 patients with 
chronic lower-back pain to receive either a facet injection 
with steroid and anesthetic or just an anesthetic block of 
the joint.23 They concluded that at 3 months both types of 
injections were equally good diagnostically and equally 
unsatisfactory for treatment of chronic lower-back pain. 
The additional literature reviewed for the current report 
suggests that there is little evidence supporting the val-
ue of intraarticular facet blocks as a therapeutic option 
for chronic low-back pain, prompting one investigator 
to comment that the efficacy of these injections was no 
greater than a sham injection.3 Datta et al.10 performed a 
systematic, evidence-based review of the literature from 
1966 through 2008 and identified 1438 articles investigat-
ing the utility of lumbar facet injections. They excluded 
W. C. Watters III et al.












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Part 13: Injection therapies, low-back pain, and lumbar fusion








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































W. C. Watters III et al.
86  J Neurosurg: Spine / Volume 21 / July 2014
studies not evaluating patients with chronic low-back 
pain of more than 3 months’ duration that was diagnosed 
as facet-mediated pain by the double-injection technique, 
with a greater than 80% pain relief threshold. Six RCTs 
and 15 observational studies were identified that evalu-
ated the effectiveness of lumbar intraarticular facet injec-
tions. These studies were rejected due to poor methodol-
ogy and failure to use the double-injection technique to 
confirm the diagnosis. Based on this systematic review 
of low-quality evidence, the authors concluded that there 
was no role for intraarticular facet injections as a treat-
ment modality. This conclusion was supported by the up-
date of the Cochrane Review published by Staal et al. in 
2009.32 These authors identified moderate-level evidence 
that facet joint injections with steroids are no more ef-
fective than placebo injections for relief of pain and dis-
ability.
The evidence for therapeutic efficacy is better for me-
dial nerve blocks of the lumbar facet joint. In their sys-
tematic review, by Datta et al. also evaluated the role of 
lumbar facet nerve blocks as a therapeutic intervention.10 
They identified two RCTs that met inclusion criteria but 
no observational studies. Manchikanti et al. performed a 
double-blinded RCT of 120 patients with facet-mediated 
low-back pain of greater than 6 months’ duration diag-
nosed using the double-injection technique and an 80% 
relief threshold.22 All patients underwent a fluoroscopi-
cally guided injection of the medial nerve. Group I (n = 
60) received anesthetic only and Group II (n = 60) re-
ceived anesthetic and steroid. Half of each group also re-
ceived Sarapin in the injectant. Multiple injections were 
performed at the discretion of the treating physician over 
1 year. Validated outcome measures including the VAS 
and ODI were used along with nonvalidated measures of 
drug usage and return-to-work status. An intent-to-treat 
analysis was used to evaluate the data at final follow-
up. Patients received up to 5 injections over the 1-year 
period with an average of 3.4 injections per patient. Im-
proved pain scores, with over 50% pain relief reported in 
over 80% of the participants, were observed at 3, 6, and 
12 months after the first injection when compared with 
baseline; however, no differences were observed between 
treatment groups. The ODI results were also significantly 
improved at 3, 6, and 12 months in all groups but with 
no differences between treatment groups. There was no 
significant decrease in opioid use observed in any group. 
These results support the premise that patients may ex-
perience significant pain relief from multiple injections 
for up to 44–45 weeks, with each injection providing on 
average of 15 weeks of pain relief for low-back pain and 
increased function as measured by the ODI. This study, 
an equivalence study that did not include a placebo con-
trol, provides moderate evidence that medial nerve injec-
tions confer short-term relief of chronic facet-mediated 
low-back pain. In a 2-year follow-up study of this same 
group of patients, Manchikanti et al. demonstrated that 
outcomes were sustained in both groups.21 Pain relief of 
greater than 50% and functional improvement of greater 
than 40% were seen in 85% of Group I and 90% of Group 
II at 18 and 24 months. Continued need for repeated in-
jections, with an average of 5 or 6 injections over the 
study period and duration of effect of 19 weeks, was seen 
in the longer follow-up.21
Ablation of the medial nerve, through radiofrequency 
thermocoagulation, is a variant of the facet nerve block. 
In the previous review of this topic, several papers were 
found testing the ability of facet blocks to predict outcomes 
from radiofrequency thermocoagulation.27 Gallagher et al. 
performed a prospective, double-blinded RCT on 41 pa-
tients who reported either a strong or equivocal response to 
diagnostic facet blocks.13 These 41 patients received either 
radiofrequency ablation with an anesthetic or just an anes-
thetic injection. Outcomes were assessed using the McGill 
Pain Questionnaire and VAS at 1 and 6 months. Patients 
who were strongly positive on facet blocks and received 
radiofrequency ablation did statistically better on both out-
come measures at both times than those who were poor 
responders to facet blocks and received ablation. Van Kleef 
et al. randomized 31 patients who had responded strongly 
to facet blocks into two groups: one received radiofrequen-
cy ablation and the other received a sham control.33 Both 
patients and treating doctors were blinded as to treatment 
who was in the control group. Outcomes were assessed us-
ing the VAS and ODI and by quantification of the amount 
of narcotic used. Outcomes were statistically superior in 
the radiofrequency group over the control at 3, 6, and 12 
months. In a larger blinded RCT of 70 patients who had re-
sponded to facet blocks, Leclaire et al. measured outcomes 
after radiofrequency ablation using the VAS, ODI, and Ro-
land-Morris disability questionnaire and found that results 
were superior only at 2 weeks, indicating no superiority for 
radiofrequency ablation for long-term relief of lower-back 
pain in this study.16 Nath et al. conducted a randomized, 
double-blinded study of patients with chronic low-back 
pain of 2 years’ duration in whom conservative treatment 
failed.24 They included only patients with facet-mediated 
low-back pain, diagnosed by the double-block technique 
and a threshold of greater than 80% pain reduction. From 
a potential population of 376 candidates, only 40 patients 
fulfilled all the diagnostic criteria. These patients were ran-
domized into a treatment group (n = 20), receiving active 
radiofrequency ablation, and a placebo group (n = 20), un-
dergoing an identical sham procedure. Primary outcome 
measures included a VAS pain scale and a nonvalidated, 
self-reported 1- to 6-point global improvement scale. Lum-
bar range of motion and a 6-point quality of life scale were 
used as secondary outcome measures. Generalized pain, 
low-back pain, and referred pain were all significantly re-
duced in the treatment group compared with the control 
group at 6 months’ follow-up. Although this is an under-
powered study, the strict diagnostic inclusion criteria lend 
strength to its conclusions. This paper provides moderate 
evidence for the effectiveness of facet radiofrequency ab-
lation in the short-term treatment of facet-mediated back 
pain.
Despite the increased diagnostic rigor seen more fre-
quently in the newer literature (the double blocks and the 
80% threshold for pain reduction), no new studies have 
appeared to suggest that diagnostic facet blocks can ef-
fectively predict the outcomes of surgical fusion in pa-
tients with chronic low-back pain from lumbar degenera-
tive disease.
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Use of Local Lumbar Injections (TPIs) in the Treatment of 
Chronic Low-Back Pain Due to Degenerative Disease of 
the Lumbar Spine
In the previous review of TPIs for chronic low-back 
pain, 4 Level II RCTs of small patient numbers were 
presented.8,14,15,31 In a very small study, Hameroff et al. 
randomized, in a double-blind fashion, 15 patients into 
3 groups: Group 1 received bupivacaine TPIs, Groups 2 
received etidocaine injections, and Group 3 received a sa-
line control injection.15 Subjective reports of pain were 
obtained at 15 minutes, 1 day, and 7 days after injection. 
Trigger point injections with anesthetic were more effec-
tive than those with saline. Sonne et al.31 prospectively 
randomized 30 patients with at least 1 month of lower-
back pain into 2 groups in a double-blinded study: Group 
I received an injection of methylprednisolone with ligno-
caine and Group II received an injection of isotonic sa-
line. Outcome measures were the VAS and lumbar range 
of motion. Significant decreases in VAS scores were seen 
in the anesthesia/steroid group while there was no dif-
ference between the two groups in terms of range of mo-
tion. Garvey et al. performed a randomized, double-blind 
evaluation of 63 patients with low-back pain unrespon-
sive to 4 weeks of conservative care.14 He divided the pa-
tients into 4 groups: Group I was treated with lidocaine 
TPIs, Group II with lidocaine and steroid TPIs, Group III 
with dry needling, and Group IV with acupressure and 
vapocoolant. More patients reported decreased pain in 
response to acupressure and coolant (63%) than to drug 
TPIs (42%), but the difference was not significant. The 
authors concluded that TPIs have some potential value in 
treating lower-back pain but that injecting a drug was not 
necessary. Collée et al., in a double-blind study, randomly 
assigned 41 patients to receive TPIs with 0.5% lignocaine 
or saline.8 Outcome measures were the VAS and a pain-
intensity scores measured 2 weeks after injection. The 
group receiving the anesthetic had a significantly bet-
ter decrease in pain than did the saline group. For all of 
these studies, it should be noted that none of the patient 
groups fulfilled a definition of chronic lower-back pain 
(> 3 months’ duration). In reviewing the literature for the 
current review, no high-quality studies on the efficacy of 
TPIs were found since the original Guideline publication. 
There have, however, been 2 published systematic reviews 
that focused partially or completely on TPIs (see Table 3).
In 2005 Furlan et al. published a Cochrane Review 
focusing on acupuncture and dry-needling for both 
acute and chronic low-back pain and reviewed the lit-
erature from 1996 to February 2003.12 While 35 RCTs 
were identified, only 20 of these were in English and all 
of the RCTs were felt to have significant methodological 
flaws. With respect to dry needling for chronic low-back 
pain, the authors concluded that the evidence was insuf-
ficient and of exceedingly poor quality to formulate any 
meaningful recommendations. A more contemporary 
Cochrane Review of injection therapy for subacute and 
chronic low-back pain by Staal et al. included TPIs as a 
treatment alternative for chronic low-back pain patients.32 
The literature published between 1999 and 2007 was re-
viewed. The authors concluded, based on limited data, 
that TPIs with steroids are no more effective than pla-
cebo injections for pain relief and improvement of dis-
ability. They stated that there was insufficient evidence 
to support the use of injection therapy for subacute and 
chronic low-back pain without radiculopathy regardless 
of type and dosage. The studies reviewed in the original 
Guidelines as well as these 2 systematic reviews suggest 
no significant differences in treatment effect exist among 
the uses of an anesthetic, an anesthetic and steroid, or dry 
needling with TPIs. Any improvement seen with these 
techniques was only apparent in acute cases of low-back 
pain. No evidence was available to support the effective-
ness of TPIs in the treatment of chronic low-back pain.
Summary
Based on the literature reviewed for the original 
guideline publication as well as this updated review, there 
is weak evidence that ESIs provide short-term relief of 
pain in patients with chronic low-back pain from degen-
erative lumbar disease. There is evidence that caudal ESIs 
are an option for decreasing pain for greater than 6 weeks 
in patients with chronic low-back pain from degenerative 
lumbar disease (Level III evidence).
Based on the original guidelines as well as this up-
dated review, there is moderate evidence to recommend 
that the diagnosis of facet-mediated back pain be made 
with the double-injection technique and a greater than 
80% improvement threshold (Level II evidence). There 
is moderate evidence supporting a recommendation that 
diagnostic facet blocks be used to predict a good response 
to facet medial nerve ablation by thermocoagulation for 
facet-mediated chronic low-back pain (Level II evidence). 
There is moderate evidence suggesting that there is no 
role for intraarticular facet injections in the treatment of 
chronic low-back pain from lumbar degenerative disease 
(Level II evidence against). There is moderate evidence 
supporting the use of facet medial nerve blocks to achieve 
short-term pain relief for patients with facet-mediated 
chronic low-back pain from degenerative lumbar disease 
(Level II evidence). There is moderate evidence that facet 
medial nerve ablation produces a short-term decrease 
(3–6 months) of facet-mediated chronic low-back pain 
(Level II evidence).
There is no evidence to support a recommendation 
that diagnostic blocks are useful predictors of surgical 
outcomes following lumbar fusion.
Based on the original guidelines as well as this up-
dated literature review, there is no evidence to support the 
use of TPIs with a dry-needling technique, with anesthet-
ics alone or accompanied by steroids, in the management 
of patients suffering from chronic low-back pain second-
ary to degenerative lumbar disease (Level IV evidence).
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